245 filings
424B5
LIXT
Lixte Biotechnology Holdings Inc
3 May 24
Prospectus supplement for primary offering
5:21pm
424B5
LIXT
Lixte Biotechnology Holdings Inc
3 May 24
Prospectus supplement for primary offering
5:20pm
EFFECT
LIXT
Lixte Biotechnology Holdings Inc
3 May 24
Notice of effectiveness
12:15am
S-3
LIXT
Lixte Biotechnology Holdings Inc
Shelf registration
23 Apr 24
1:46pm
8-K
3e0 hujnvco8vh6wefe
27 Mar 24
Other Events
7:51pm
8-K
opafhi53okr2phjz8y9
22 Mar 24
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
11:17am
8-K
vdti41re
27 Feb 24
Professor René Bernards to Present New Pre-Clinical Data
4:59pm
8-K
2o75nq
26 Feb 24
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
10:48am
8-K
t9ktvwhe
30 Jan 24
Other Events
12:00am
8-K
nf251
28 Nov 23
Departure of Directors or Certain Officers
5:21pm
8-K
7n31a00k9
13 Nov 23
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
2:28pm
8-K
06fjzl70bwrwswwdu3
17 Oct 23
Entry into a Material Definitive Agreement
5:27pm
DEFA14A
4r94or adafv5
10 Oct 23
Additional proxy soliciting materials
3:55pm
8-K
hsfew5uy
4 Oct 23
Termination of a Material Definitive Agreement
9:05pm
8-K
15gqipvgci7lhg5a
27 Sep 23
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
6:15am